Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program

BACKGROUND: Disease modifying treatments (DMT) for MS such as interferon beta (IFNβ) have been shown to reduce the risk for disease progression. Therefore adherence to treatment is essential for treatment outcome.Here we want to evaluate if participation in a patient management program (PMP) improve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Neurol
Main Authors: Katsarava, Zaza, Ehlken, Birgit, Limmroth, Volker, Taipale, Kirsi, Patel, Sarita Noemi, Niemczyk, Gabriele, Rehberg-Weber, Karin, Wernsdörfer, Colin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580346/
https://ncbi.nlm.nih.gov/pubmed/26395989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0426-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados